Department of Interventional Radiology, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Street, Zhongshan District, Dalian 116001, China.
World J Surg Oncol. 2013 Sep 9;11:222. doi: 10.1186/1477-7819-11-222.
Colorectal cancer (CRC) is one of the most common cancers worldwide. The majority (approximately 60%) of patients with CRC will eventually develop liver metastases, which remain the most common cause of mortality in these patients. This study aimed to evaluate the therapeutic effect and tolerability of gelatin sponge particle (GSP)-mediated chemoembolization in the treatment of colorectal liver metastases after systemic chemotherapy failure.
This was a single-center retrospective study of 15 patients with colorectal liver metastases, who underwent GSP-mediated chemoembolization with 50 mg of lobaplatin during the period December 2009 to December 2010 in the Department of Interventional Radiology, Affiliated Zhongshan Hospital of Dalian University. Clinical data were retrieved, and the therapeutic effect and tolerability of the treatment were evaluated.
All 15 patients with colorectal liver metastases completed the GSP-mediated chemoembolization. The therapeutic effect and tolerability were evaluated 3 months after the initial procedure. The tumor lesions in all patients showed various levels of necrosis and shrinkage. According to the Response Evaluation Criteria in Solid Tumors (RECIST), one patient achieved complete response (CR), eleven patients achieved partial response (PR), and three patients achieved stable disease (SD). The overall response rate (CR + PR) was 80%.
GSP-mediated chemoembolization is well tolerated and has a good short-term response rate (80%) in the treatment of colorectal liver metastases after systemic chemotherapy failure. Collectively, further study of the long-term effect of GSP-mediated chemoembolization in colorectal liver metastasis in a large cohort is warranted.
结直肠癌(CRC)是全球最常见的癌症之一。大多数(约 60%)CRC 患者最终会发展为肝转移,这仍然是这些患者死亡的最常见原因。本研究旨在评估在全身化疗失败后,使用明胶海绵颗粒(GSP)介导的化疗栓塞治疗结直肠癌肝转移的治疗效果和耐受性。
这是一项单中心回顾性研究,纳入了 2009 年 12 月至 2010 年 12 月在大连大学附属中山医院介入放射科接受 50mg 洛铂 GSP 介导化疗栓塞治疗的 15 例结直肠癌肝转移患者。检索临床资料,评估治疗的疗效和耐受性。
所有 15 例结直肠癌肝转移患者均完成 GSP 介导的化疗栓塞。初始治疗后 3 个月评估疗效和耐受性。所有患者的肿瘤病灶均显示不同程度的坏死和缩小。根据实体瘤反应评估标准(RECIST),1 例患者达到完全缓解(CR),11 例患者达到部分缓解(PR),3 例患者达到疾病稳定(SD)。总缓解率(CR+PR)为 80%。
GSP 介导的化疗栓塞治疗在全身化疗失败后治疗结直肠癌肝转移具有良好的短期疗效和耐受性(缓解率为 80%)。需要进一步研究 GSP 介导的化疗栓塞治疗结直肠癌肝转移的长期效果。